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Summary The cycin kinase inhibitor WAFl CIPI, also termed CDKN1. mediates p53-induced cell cycle
arrest in response to DNA damage. This property makes it an attractive tumour-suppressor candidate for a
p53-associated tumour-suppressor gene. In order to investigate the role of WAFLiCIPl in the pathogenesis of
primary human brain tumours we performed single-stranded conformation polymorphism (SSCP) analysis and
direct sequencing of exon 2 of the gene in a representative series of 158 brain tumours and corresponding
blood samples. In addition, all tumours were examined for mutations in exons 5-8 of the p53 gene. Analysis
of WAFl CIPI revealed multiple polymorphisms, the most abundant being AGC->AGA (Ser->Arg) at
codon 31 with an allele frequency of 8.5%. Less common polymorphisms included GTG+GGG (Val+Gly)
at codon 25. GCC-)ACC (Ala+Thr) at codon 64, CGC-*CTC (Arg->Leu) at codon 32, GGC+AGC
(Gly-*Ser) at codon 14 and GCG-*GTG (Ala+Val) at codon 39 each with an allele frequency of 0.3%.
These polymorphisms were all located in a conserved region of exon 2. Two of the polymorphisms were also
seen in a group of 157 healthy controls indicating that WAFI ,CIPI polymorphisms do not predispose to
cancer. None of the tumours included in our senres showed a somatic mutation in WAFi CIPI. All samples
were also analysed for loss of heterozygosity on the short arm of chromosome 6 in the region of the
WAFi CIPI locus. Allelic loss was observed in only one patient with a glioblastoma. Mutations in the p53
gene were found in 22 of 158 tumours. No association was found between any polymorphism of the
WAFI CIPl gene. p53 mutations and histopathological tumour type. Our data indicate that WAFI CIPI
mutations are probably not involved in the formation of primary human brain tumours.
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The p53 tumour-suppressor gene is frequently mutated in
human brain tumours (Louis, 1994). Wild-type p53 plays a
major role in the cellular response to DNA damage, either by
inducing a GI arrest and subsequent DNA repair or by
inducing apoptosis (Lane, 1993): Some of these effects are
likely to be executed by genes which act as downstream
mediators of p53 (Smith et al., 1994). Recently a link
between p53 and cell cycle arrest was provided by the cloning
of the cycin kinase inhibitor WAFI/CIPI, also called
CDKN1 or p210l (El-Deiry et al., 1993; Harper et al., 1993).
WAFl/CIPl transcription is directly induced by p53 in res-
ponse to DNA damage. It blocks the GI-S transition by
inhibiting the activity of multiple cyclin-cyclin dependent
kinase complexes (Xiong et al., 1993; Di Leonardo et al.,
1994; El-Deiry et al., 1994). Further, the WAFI/CIPI gene
product, p21, exerts a growth-suppressing effect if expressed
under the control of a heterologous promoter (El-Deiry et
al., 1993).
This induction by p53 and its function as a negative
regulator of the cell cycle make WAF1ICIPl an attractive
candidate for a tumour-suppressor gene. Alterations of
WAFl/CIPl function could constitute an alternative mech-
anism to p53 inactivation. Thus WAFI/CIPI mutations may
contribute to the development of those tumours who have
retained wild-type p53 alleles. Several studies have demon-
strated a high incidence of p53 mutations in human gliomas,
but have also documented that many gliomas express wild-
type p53 (von Deinling et al., 1992; Rubio et al., 1993;
Louis, 1994). In order to evaluate the hypothesis that WAF1/
CIPI mutations interrupt the p53-mediated pathway in brain
tumours with wild-type p53, we performed single-strand con-
formational polymorphism (SSCP) analysis of both the
WAFl/CIPl gene and the p53 gene in 158 human brain
tumours. In addition we assessed these tumours for allelic
loss in the WAFl/CLPl region on chromosomal arm 6p.
Materials and methods
Tumour specimens, histopathologv and control DNA
Tumour and corresponding blood samples were obtained
from patients at the Massachusetts General Hospital, Boston,
the University Hospital, Zurich and the University Hospital,
Bonn. All tumours were classified by a neuropathologist
(AvD) according to the revised WHO guidelines (Kleihues et
al., 1993). The specimens were examined microscopically
before phenolic DNA extraction (Sambrook et al., 1989).
The series of 158 tumours included 54 glioblastomas WHO
grade IV, 15 anaplastic astrocytomas WHO grade III, nine
astrocytomas WHO grade II, 22 pilocytic astrocytomas
WHO grade I, 20 meningiomas WHO grade I, five atypical
meningiomas WHO grade II, one anaplastic meningioma
WHO grade III, 12 primitive neuroectodermal tumours
WHO grade IV (including ten medulloblastomas), five
oligodendrogliomas WHO grade II, two anaplastic oligoden-
drogliomas WHO grade III, six oligoastrocytomas WHO
grade II, three anaplastic oligoastrocytomas WHO grade III
and one each of schwannoma, neurofibroma, gangliocytoma
and pleomorphic xanthoastrocytoma. Normal control DNAs
were obtained from 157 unrelated healthy whites from Ger-
many.
SSCP analysis
For analysis of the WAFI,1CIPl gene primers for two over-
lapping portions of exon 2 were generated based on the
published cDNA sequence (El-Deiry et al., 1993). The
amplified region constitutes 87% of the coding sequence of
the WAFl/CIPl gene. The primers were 5'-GTCAGAACC-
GGCTGGGGATG and 5'-CTCCTCCCAACTCATCCCGG
for fragment 1 (272 bp) and 5'-TGGCCTGCCCAAGCTC-
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spectively. Polymerase chain reaction (PCR) was performed
in a volume of 10 JLI containing 10 ng of DNA, 50 mM
potassium chloride. 10 mm Tris-HCl. 200 mM of each dNTP,
0.lI% gelatin, 20 pmol of each primer. 1.0 mm magnesium
chloride and 0.025 U of Taq polymerase. Initial denaturation
at 94°C for 3 min was followed by 30 cycles on an automated
thermal cycler (Hybaid. Omnigene. USA). These included
denaturation at 94°C for 30 s. annealing at 57C for 40 s and
extension at 72°C for 40 s. A final extension step at 72°C for
10 min was added. SSCP was performed on a sequencing
apparatus (Pokerface II, Hoefer. San Francisco, USA) using
12% acrylamide. run at 20W. 14 h at 4°C for fragment 1.
and 8% acrylamide run at 2 W. 14 h at 25°C for fragment 2.
Silver staining of the gels was performed as previously des-
cnrbed (von Deimling et al.. 1993; Bender et al.. 1994).
Analysis of the p53 gene was camred out as reported
elsewhere (von Deimling et al.. 1992).
Direct sequencing
Aberrantly migrating SSCP bands were excised and the DNA
was extracted as descnrbed (Sambrook et al., 1989). After
reamplification with the same set of primers the PCR prod-
ucts were sequenced on a semiautomated sequencer (Applied
Biosystems. model 373) using the corresponding Taq cycle
sequencing kit. Each amplicon was sequenced bidirectionally.
Microsatellite anal}ysisfor loss ofheterozvlgositv
The following primer pairs on chromosome 6p were used for
a non-radioactive microsatellite analysis: D6S497 at 6p22.3-
p21 and D6S105 at 6p22-p2l.3. PCR products were
separated on 8% denaturing acrylamide gels and silver
stained. Loss of heterozygosity (LOH) was scored as
previously descnrbed (Louis et al.. 1992).
Results
SSCP analysis and direct sequencing of the WAFI CIPI gene
were conducted with two primer pairs generating fragments
of 272 bp and 223 bp respectively. These fragments encom-
pass 87% of the coding sequence. None of these tumours
exhibited a somatic mutation of the WAFI 'CIPI gene. How-
ever. we found six different polymorphisms which resulted in
eight observed haplotypes (see Figure 1). These patterns were
identical in both tumour and constitutional DNA of all
patients with aberrant SSCP fragments. An overview of allele
distribution and observed haplotypes is given in Tables I and
II.
The study revealed six distinct polymorphisms designated
A-F with two alleles each. Allele frequencies were 0.91 0.09
for Al A2. and 0.997 0.003 for the polymorphisms B-F. The
distribution of these polymorphisms yielded eight different
haplotypes of which I and II were predominant. In this series
haplotype I was detected in 80.4%. II in 15.8% and III to
VIII in one patient each (0.63%).
In order to compare the rate of polymorphisms in the
tumour group with the normal population we analysed a
panel of DNAs from 157 healthy whites from Germany.
Haplotype frequencies were I 80.2%. II 18.5% III and IV
0.64% (one patient each). The incidence of polymorphisms
was similar in both tumour and control groups for Al,A2
and B B2. The polymorphisms C2. D2, E2 and F2 were
only observed in the tumour group. Patients with the I and II
haplotype shared a similar spectrum of histopathological
tumour types and were not associated with a specific tumour
entity.
Microsatellite analysis for LOH in the area ofWAFI,'CIPI
gene on 6p2l.2 revealed a total of 106 informative cases in
the brain tumour group. LOH was seen in only one patient
with a glioblastoma.
Mutational analysis of exons 5-8 of the p53 gene in the
primary brain tumours revealed 23 somatic sequence altera-
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Figue 1 Analysis of the WAFI CIPI gene in brain tumours. (a)
SSCP patterns of the WAFI CIPI gene in brain tumours. The
corresponding polymorphisms are listed in Table II. (b) Sequence
analysis of the F2 allele in codon 39. The sequence of the
prevalent Fl allele (C) is indicated.
Table I Polymorphisms in the WAFI CIPI gene
Allele Allele frequency Codon Sequence Amino acid
Al 91% 31 AGC Ser
A2 9°/ 31 AGA Arg
BI 99.7% 25 GTG Val
B2 0.3% 25 GGG Gly
Cl 99.7% 64 GCC Ala
C2 0.3%0 64 ACC Thr
Dl 99.7% 32 CGC Arg
D2 0.30o 32 CTC Leu
El 99.7% 14 GGC Gly
E2 0.3% 14 AGC Ser
F1 99.7O/o 39 GCG Ala
F2 0.3 0/ 39 GTG Val
Codons affected. DNA sequence, amino acid exchange and allele
frequencies are given for the six observed polymorphisms in the
WAFI CIPI gene.
tions in 22 tumours, corresponding to an overall mutation
frequency of 13%. Mutations were seen in 11/54 glioblas-
tomas, 8 24 astrocytomas, two of nine oligoastrocytomas and
one of ten medulloblastomas. The 23 mutations consisted of
19 transitions, three transversions and one deletion of a
single basepair resulting in a frameshift. Noteworthy are six
identical C-*T transitions in codon 273 in glial tumours,
indicating that this codon represents a mutational hotspot in
gliomas. Two G-*A transitions each were found in codons
175 and 248 of four glioblastomas. One anaplastic oligoast-
rocytoma had mutations in codons 249 and 281. There was
no association between any one of the WAFI/CIPI polymor-
phisms and mutations in exons 5-8 of the p53 gene.1232u~i beWFICP gm
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Table H WAFI/CIPI haplotypes in 158 human brain tumours
Allele
Haplotype distribution Frequency
I Al/A1,BI/B1,CI/C1,D1fD1,E1fE1,F1/FI 127/158 (80.4%)
II Al/A2B1/B1,CI/Cl,D1/D1,E1/E1,FI/FI 25/158 (15.8%)
III A2/A2,BI/BJ,CI/C1,DI/D1,EIE1,F1/FI 1/158 (0.63%)
IV Al/AI,B1/B2,C1/C1,D1/DI,E1/E1,F1/FI 1/158 (0.63%)
V Al/Al,BI/Bl,CI/C2,DI/Dl,El/El,Fl/FI 1/158 (0.63%)
VI Al/A1,B1/B1,C1/C1,D/D2,E1/E1,F1/FI 1/158 (0.63%)
VII Al/A1,BJ/B1,C1/Cl,D1/D1E1/E2,FI/FI 1/158 (0.63%)
VIII Al/A,BJ/B1,C1/Cl,D1/D1E1/E1,F1/F2 1/158 (0.63%)
Allele distribution and frequencies are isted for the eight observed haplotypes. The
rare alelks characteristic for the haplotypes are given in boldface.
We report on a large series of brain tumours examined for
mutations in the WAFI/CIPI gene. No somatic mutations
were found in 158 patients with brain tumours. Since we
have only screened 87% of the coding sequence of the gene,
we cannot exclude mutations in other regions, but an exten-
sive study of the entire coding region of WAFI/CIPi in
non-cerebral tumours also failed to detect mutations (Shio-
hara et al., 1994). In addition, allelic loss of the WAFI/CIPI
region of chromosomal arm 6p was extremely rare. We
therefore conclude that WAFI/CIPI mutations are probably
not involved in the formation of human brain tumours.
While no somatic mutations were detected in our study, we
found a surprising number of different non-conservative
polymorphisms. The most frequent polymorphism Al/A2 has
been described in previous reports (Chedid et al., 1994;
Shiohara et al., 1994). In our series the frequencies for Al/A2
were 0.91/0.09 resulting in 15.8% heterozygotes. This Ser/
Arg polymorphism in codon 31 has been reported with a
similar incidence (Chedid et al., 1994; Shiohara et al., 1994).
We detected five additional polymorphisms (B-F) in the
region of codons 14-64. All polymorphisms result in altera-
tions of the amino acid sequence (see Table I). Two other
studies have failed to detect any ofthe variants except for the
common Al/A2 polymorphism (Chedid et al., 1994; Shiohara
et al., 1994). AM of these polymorphisms reside in an area of
greater than 90% homology at the protein level with the
murine homologue, which is thought to encode a DNA-
binding zinc-finger domain (El-Deiry et al., 1993; Huppi et
al., 1994). This observation raises the possibility that these
polymorphisms encode functionally distinct proteins, but
transfection studies have shown no difference in the tumour-
suppressor abilities of the serine and arginine alleles (Al/A2)
in a lung cancer cell lne (Chedid et al., 1994). Intrestingly,
the A2 allele corresponds to the mouse sequence. The other,
rarer polymorphisms, however, await functional characterisa-
tion. A recent report localised the Cdk kinase inhibiting
activity to the N-terminal region ofWAFI/CIPI (Chen et al.,
1995). All polymorphisms described in the present study
reside in the proposed Cdk kinase inhibiting domain.
Therefore, these polymorphisms may be useful in studying
this particlar function ofWAFI/CIPI in naturally occurring
variants. Nonetheless, the occurrence of the B2 allele in a
healthy individual argues against a pathogenic effect of this
variant Indeed, comparison of the allelic distribution in the
tumour and control groups revealed a nearly identical dis-
tribution for the Al/A2 and BI/B2 alleles, and while the
other, rarer polymorphisms were only seen in tumour
patients, this assocation was not sipificant. Thus, although
our study has demonstrated that somatic WAFl/CIPl muta-
tions do not occur in brain tumours and that none of the
various WAFI/CIPI polymorphisms predisposes to tumour
formation, the study stresses the importance of combined
analysis of paired tumour/constitutional DNA samples to
avoid interpreting these multiple non-conservative polymor-
phisms as somatic mutations.
Mutations in the p53 gene were detected in 11/54 glioblas-
tomas, 8/24 astrocytomas, two ofnine oligoastrocytomas and
one of ten medulloblastomas. These figures are similar to
previous studies (Ohgaki et al., 1993; Louis, 1994). No
association between p53 mutations and WAFl/CEPl poly-
morphisms was noted. Therefore, while alterations of other
components in the p53 cascade, such as MDM2 amplification
may provide an alternative means for inactivating the p53
pathway (Reifenberger et al., 1993), WAFI/CIPl does not
appear to have such a role in human brain tumours.
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